Noema Pharma
Business Services · Switzerland · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Barfüsserplatz 3, Basel, Basel-City, 405...Website
www.noemapharma.comRevenue
$6.1 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
2
1
1
1
1
About Noema Pharma
Noema Pharma is a clinical-stage biotech company advancing a portfolio of transformative, first-in-disease therapeutics targeting neuroscience-based conditions with high unmet need. Noema has four programs currently in active Phase 2 clinical trials evaluating seizures in Tuberous Sclerosis Complex, pain in Trigeminal Neuralgia, Tourette syndrome and vasomotor symptoms plus CNS-mediated symptoms of menopause with readouts expected in 2019. Noema was founded by leading venture capital firm Sofinnova Partners and is supported by current investors including Forbion, Gilde Healthcare, Invus, Jeito Capital, Polaris Partners and UPMC Enterprises.Explore more
Noema Pharma Org Chart
RL
Chief Medical Officer
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Noema Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Noema Pharma
Check if Noema Pharma has recently received funding, and reach out quickly before it becomes old news!
Noema Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Noema Pharma is spiking on competitors!
Click to see if Noema Pharma had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Noema Pharma launches new products
Earning: See what the market has to say on Noema Pharma recently announced quarterly report
Funding: Get notified immidiatlly once Noema Pharma has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
Noema Pharma is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Noema Pharma is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Noema Pharma.
Noema Pharma financials insights
Gather financial insights about Noema Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$59M
2024
Series B
$147M
Noema Pharma Tech Stack
A closer look at the technologies used by Noema Pharma
Most Recent Scoops
Open Position
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Open Position
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
Noema Pharma News & Media
Noema Pharma Announces Phase 2a Study Results with Cendifensine in Women with Vasomotor Symptoms (Hot Flashes) Due to Menopause
Cendifensine demonstrates 92% reduction in number of hot flashes Cendifensine demonstrates 92% reduction in number of hot flashesNoema Pharma Appoints Michael Samar as Chief Financial Officer
Appointment Further Strengthens Leadership Team; Follows Appointment of Volker Knappertz, M.D., as Executive Vice President of Research & Development Appointment Further Strengthens Leadership Team; Follows Appointment of Volker Knappertz, M.D., as Executive Vice President of Research & DevelopmentNoema Pharma Appoints Volker Knappertz, M.D., as Executive Vice President of Research & Development
BASEL, Switzerland, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, today announced the appointment of Volker Knappertz, M.D., as Executive Vice President of Research & Development.EQT Leads Series B Funding Extension in Swiss Biotech Noema Pharma - MarketScreener
By Dominic Chopping STOCKHOLM--Swedish buyout group EQT led a series B funding extension for Swiss biotech company Noema Pharma. Noema Pharma is developing a pipeline of therapeutics that...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Noema Pharma
Sign Up For FreeTo access detailed company insights
Noema Pharma is a clinical-stage biotech company advancing a portfolio of transformative, first-in-disease therapeutics targeting neuroscience-based conditions with high unmet need. Noema has four programs currently in active Phase 2 clinical trials evaluating seizures in Tuberous Sclerosis Complex, pain in Trigeminal Neuralgia, Tourette syndrome a... Read More
